Programme of cooperation in science & technology
Indo Swiss Joint Research Programme (ISJRP)
EXCHANGE GRANT REPORT
Grant No.: RF23
PART 1 - GENERAL INFORMATION
Functional characterization of cis
acting elements in the Promoter
CYP2C19, Promoter, transcription factor, transcription
PART 2 - EXCHANGE PARTICIPANT(S) DETAILS
2.1 Visiting student
Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)
2.3 Hosting scientist
Institute of Biotechnology - University of Lausanne
PART 3 - SCIENTIFIC & TECHNICAL INFORMATION
3.1 Purpose of visit:
1. To exchange expertise for exploring the transcription factors and their binding sites interaction in a promoter
region of a gene using gel shift assays or electrophoretic mobility shift assays.
2. To undergo training in in silico
analysis of the enzyme and substrates interaction to predict the inhibitory
3.2 Short description of work carried out during the visit
The work plan was modified slightly to optimize the methodology described in our proposal for effective and
timely completion of the work, but the objectives remained the same. We used Cy-3
labelled oligos (labelled on 5’-end of forward strand of each double strand oligo) for binding sites instead of the biotin/P32 labelled oligos, and thus we avoided usage of hazardous radioactive material i.e. P32and avoided the blotting step with biotin labelled oligos. Trial experiments with HepG2 and HeLa nuclear extracts have shown that the usage of Cy-3
labelled oligos is sensitive enough to detect the DNA-protein interactions in a gel shift. Briefly, the following work has been being carried out.
1. Purchase and annealing of the single stranded oligos to form a double stranded oligos representing the binding
site of transcription factor. The list of additional oligos used for creating binding site for transcription factors other than the ones described in the proposal are given in Table 1.
2. HepG2 cell lines were maintained till 70-80% confluent and nuclear extract was prepared as the protocol
mentioned in the proposal and was quantified for amount of proteins using Bradford reagent.
3. Standardisation of the gel shift assays has been carried out with varying amount of protein, poly dI.dC, and
salt concentration as mentioned in the proposal.
4. Gel shift assays for the predicted transcription factors from CYP2C19 promoter region as mentioned in Table
1 has been carried out, with super shift assays for CCAAT enhancing binding protein beta (CEBPB) and Cyclic AMP responsive element binding protein (CREB) binding sites.
5. In silico
analysis of CYP2C19 and its substrates has been carried out using the Swissdock software developed
at the Swiss institute of bioinformatics, and the results were cross-validated with the autodock and autodockvina softwares.
Table 1. List of oligos representing the sequences of transcription factor binding site in CYP2C19 promoter
region used for EMSA
S.No Sequence of forward strand Sequence of Reverse strand
5' CCA TCG TGG CGC ATT 5' AGA GAT AAT GCG CCA Cyclic AMP responsive element beta ATC TCT 3'
(CREB) binding site with normal allele in CYP2C19 promoter
5' CCA TCG GGG CGC ATT 5' AGA GAT AAT GCG CCC Cyclic AMP responsive element beta ATC TCT 3'
(CREB) binding site with variant allele in CYP2C19 promoter
5' AAC ATT GTG CAA TTG 3' 5' CAA TTG CAC AAT GTT 3'
CCAAT enhancing binding protein beta (CEBPB) binding site with normal allele in CYP2C19 promoter
5' AAC ATT GGG CAA TTG 5' CAA TTG CCC AAT GTT 3'
(CEBPB) binding site with variant allele in CYP2C19 promoter
The outcomes of the work being carried out are as follows:
1. We observed differences in the interaction of normal and variant oligos representing the CREB and
CEBPB binding sites with the nuclear protein in gel shift assays. This has been confirmed for CREB by competition experiments.
2. For both of these sites, a higher affinity of the nuclear protein was found with variant “mutated” oligos
when compared to that of the most prevalent allele sequence, represented by oligos bearing the unmutated binding sites of the corresponding transcription factors.
3. Super shift assays with CREB-2 polyclonal antibody and CEBPB antibody revealed specific interaction
4. This supports our earlier observations of increased luciferase activity with the constructs having variant
allele in CREB binding site, suggesting the increased luciferase activity might be resulting from the increased interaction of CREB to its binding site in the presence of variant allele and thus increasing the transcription of the CYP2C19
5. This could explain how the variations in the cis
acting elements in the promoter region of a gene could
influences its transcription by altering the recruitment of the transcription factor to its binding site in a promoter region.
6. In silico
docking analysis of homology modeled structure of CYP2C19 with its common substrates has
revealed similar interaction of the substrates with inhibitory capacity with that of CYP2C19 (Table 2). Most of the substrates were docked into the hydrophobic pocket with residues such as ARG83, VAL25, PHE451, ALA272, ASP268, LEU341, GLY450, ILE219, GLU275, etc.
Table 2. The interaction of various substrates of CYP2C19 with CYP2C19.
reports on inhibitory
activity on CYP2C19
#1 LIG 1 N1 #0 GLU 380 OE1 #1 LIG 1 H10 3.432
Similar clusters were found using the three different docking software i.e. Swissdock, autodock, and autodockvina.
#0=target i.e. CYP2C19; #1=substrate i.e. corresponding substrate; Standard amino acid and atom symbols were used to represent the amino acid involved in
interaction. Atoms are represented by their respective symbols (like `O' for oxygen, `H' for hydrogen, `N' for nitrogen)followed by distance abbreviation in the
order of increasing distance i.e. ``A'' for alpha, ``B'' for beta, ``G'' for gamma, ``D'' for delta, ``E'' for epsilon, ``Z'' for zeta, and ``H'' for eta, followed by a digit
designating the branch direction (No digit after distance abbreviation indicates that the side chain is unbranched).
similar interaction was found between
the family members except for gliclazide which is predicted to have some inhibitory capacity as it is interacting in a similar manner that of voriconazole and omeprazole. But till now no experimental or clinical reports are not available on its inhibitory capacity.
3.4 Future collaboration with host institution
We have established a contact with Prof. Nicolas Mermod group, LBTM, University of Lausanne and Prof.
Oliver Michielin and Dr. Vincent Zoete of Swiss Institute of Bioinformatics. In future we may also plan some
studies related to the gene regulation especially for those genes of therapeutic importance. 3.5 Various comments:
The host laboratory has organized my trip and schedule very well. The lab members and secretary were very
cooperative. It was a pleasant and fruitful visit. 3.6 Projected publications/articles resulting or to result from the exchange
The findings of this project have to be communicated to a peer reviewed journal. After few more replicating
experiments to confirm the results obtained, the manuscript with the data shall be communicated.
ADULT PATIENT HISTORY FORM Kamini Ramani, M.D., P.C. Gastroenterology and Internal Medicine 99 E State Street Gloversville, NY 12078 Telephone: (518) 725-6080. NAME: ______________________________ DOB: ___/___/___ DATE COMPLETED: ___/___/___ Referred by: (Primary Care Physician’s Name): ___________________________________________ Occupation: _______________________________________ Ge
Jury recommends review of detox policy;Inquest Family of inmate who committed suicide believe he was trying to get to a hospital. [Saint John, N.B] 19 May 2007: B2. Abstract (summary)Translate"We do not agree with the jail doctor taking away Jeff's Fentanyl patch," [Ray Cormier] read. "If they had consulted with Jeff's doctor they would have found out the reasons why, including th